A systematic review of the effectiveness of adalimumab

More documents

Recommendations

Info

Ovid MEDLINE(R) 1966 to February week 2 2005 1 arthritis rheumatoid/ 2 tum?r necrosis factor.mp. 3 exp receptors tumor necrosis factor/ 4 anti tnf.mp. 5 infliximab.mp. 6 remicade.mp. 7 enbrel.mp. 8 etanercept.mp. 9 or/2-8 10 1 and 9 11 decision support techniques/ 12 markov.mp. 13 exp models economic/ 14 decision analysis.mp. 15 cost benefit analysis/ 16 or/11-15 17 10 and 16 18 limit 17 to yr=2001 - 2005 19 adalimumab.mp. 20 humira.mp. 21 or/19-20 22 1 and 21 and 16 23 18 or 22 Appendix 6 Health Technology Assessment 2006; Vol. 10: No. 42 Searches: decision-analytic models © Queen’s Printer and Controller of HMSO 2006. All rights reserved. EMBASE (Ovid) 1980 to week 8 2005 1 arthritis rheumatoid/ 2 tum?r necrosis factor.mp. 3 exp receptors tumor necrosis factor/ 4 anti tnf.mp. 5 infliximab.mp. 6 remicade.mp. 7 enbrel.mp. 8 etanercept.mp. 9 or/2-8 10 1 and 9 11 decision support techniques/ 12 markov.mp. 13 exp models economic/ 14 decision analysis.mp. 15 cost benefit analysis/ 16 or/11-15 17 10 and 16 18 limit 17 to yr=2001-2005 19 adalimumab.mp. 20 humira.mp. 21 or/19-20 22 1 and 21 and 16 23 18 or 22 157
Page 1 and 2:
A systematic review of the effectiv
Page 3 and 4:
A systematic review of the effectiv
Page 5 and 6:
Objectives: This report reviews the
Page 7:
Glossary and list of abbreviations
Page 10 and 11:
viii Glossary and list of abbreviat
Page 13 and 14:
Background Rheumatoid arthritis (RA
Page 15:
increased risk of serious infection
Page 19 and 20:
Summary RA is a common, chronic, in
Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
Page 23 and 24:
Assessment of response to DMARDs Re
Page 25 and 26:
combination with methotrexate or al
Page 27:
disease between clinic appointments
Page 30 and 31:
14 Effectiveness in juvenile arthri
Page 32 and 33:
16 Effectiveness adalimumab plus me
Page 34 and 35:
18 Effectiveness Monoclonal Antibod
Page 36 and 37:
20 TABLE 1 Description of included
Page 38 and 39:
22 TABLE 2 Quality of included RCTs
Page 40 and 41:
24 Effectiveness change in modified
Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
Page 44 and 45:
28 Effectiveness Review: Adalimumab
Page 46 and 47:
30 Effectiveness Review: Adalimumab
Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
Page 54 and 55:
38 Effectiveness etanercept trials.
Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
Page 58 and 59:
42 Effectiveness Review: Etanercept
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
Page 72 and 73:
56 TABLE 12 Description of included
Page 74 and 75:
58 TABLE 13 Quality of included RCT
Page 76 and 77:
60 Effectiveness per week and escal
Page 78 and 79:
62 Effectiveness significant advant
Page 80 and 81:
64 Effectiveness Review: Infliximab
Page 82 and 83:
66 Effectiveness Review: Infliximab
Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
Page 89 and 90:
Summary of review of existing econo
Page 91 and 92:
TABLE 20 Summary of published ICERs
Page 93 and 94:
TABLE 21 Published etanercept econo
Page 95 and 96:
TABLE 23 Published economic analyse
Page 97 and 98:
TABLE 25 Treatment sequences: adali
Page 99 and 100:
management of RA, i.e. 1st and 2nd
Page 101 and 102:
To estimate the long-term consequen
Page 103 and 104:
TABLE 32 TNF inhibitors as last act
Page 105 and 106:
TABLE 34 Basic structure of the mod
Page 107 and 108:
een quit on grounds of toxicity, ad
Page 109 and 110:
TABLE 39 Strategy set: adalimumab a
Page 111 and 112:
TABLE 43 Beta distributions for HAQ
Page 113 and 114:
TABLE 44 Early cessation of DMARDs:
Page 115 and 116:
TABLE 46 Unit costs for tests and v
Page 117 and 118:
following properties, according to
Page 119 and 120:
TABLE 52 Base case: TNF inhibitors
Page 121 and 122: TABLE 54 Base case: TNF inhibitors
Page 123 and 124: TABLE 59 Third TNF inhibitor follow
Page 125 and 126: TABLE 65 Sensitivity analyses: TNF
Page 127 and 128: TABLE 67 Sensitivity analyses: TNF
Page 129: The substantial economic impact of
Page 133 and 134: Summary Effectiveness: principal fi
Page 135 and 136: inhibitors, although the incrementa
Page 137 and 138: introduce bias which generally exag
Page 139: Adalimumab, etanercept and inflixim
Page 143 and 144: 1. Jobanputra P, Barton P, Bryan S,
Page 145 and 146: 46. Young A, Dixey J, Cox N, Davies
Page 147 and 148: tumor necrosis factor therapy in th
Page 149 and 150: arthritis: a 12-week, double-blind,
Page 151 and 152: 171. Geborek P, Crnkic M, Petersson
Page 153 and 154: 216. Schotte H, Willeke P, Mickholz
Page 155 and 156: The Health Assessment Questionnaire
Page 157 and 158: Cochrane Library (CENTRAL) 2005 Iss
Page 159 and 160: Appendix 3 © Queen’s Printer and
Page 161: TABLE 69 Studies excluded from clin
Page 164 and 165: 148 Appendix 4 TABLE 71 Meta-analys
Page 166 and 167: 150 Appendix 4 TABLE 73 Meta-analys
Page 168 and 169: 152 Appendix 4 Infliximab versus pl
Page 170 and 171: 154 Appendix 4 Infliximab plus MTX
Page 175: Ovid MEDLINE(R) 1999 to March week
Page 178 and 179: 162 Appendix 8 TABLE 78 Choi et al.
Page 180 and 181: 164 Appendix 8 TABLE 80 Kobelt et a
Page 182 and 183: 166 Appendix 8 TABLE 81 Welsing et
Page 184 and 185: 168 Appendix 8 TABLE 82 Brennan et
Page 186 and 187: 170 Appendix 8 TABLE 84 Chiou et al
Page 188 and 189: 172 Appendix 8 TABLE 86 Kobelt et a
Page 191 and 192: Appendix 9 © Queen’s Printer and
Page 193: TABLE 92 Strategy set: infliximab a
Page 196 and 197: 180 Appendix 10 TABLE 95 Variation
Page 198 and 199: 182 Appendix 10 Variation 2 For thi
Page 222 and 223:
206 Appendix 10 Variation 11 In thi
Page 224 and 225:
208 Appendix 10 TABLE 137 Variation
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 245:
Additional ongoing/unpublished tria
Page 248 and 249:
232 Health Technology Assessment re
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 261 and 262:
Members Chair, Professor Tom Walley
Page 263 and 264:
Members Chair, Professor Bruce Camp
Page 266:
Feedback The HTA Programme and the
show all

A systematic review of the effectiveness of adalimumab

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?